One week after expanding its neurodegenerative diseases partnership with Bristol Myers Squibb, Evotec entered into a drug discovery collaboration for metabolic diseases with Eli Lilly, focusing on kidney disease and diabetes.
The collaboration between the two companies, which is currently set for three years, has a potential value of $1 billion, which covers up to five programs. Lilly, which has a significant presence in the diabetes field, will leverage Germany-based Evotec
